Viridian Therapeutics Inc
VRDN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.78B
Close$
$-11.50
160.3% downside
Current Fair Value
160.3% downsideOvervalued by 160.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.78 Billion |
|---|---|
| Enterprise Value | $1.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.32 |
| Beta | 0.9 |
| Outstanding Shares | 102,211,657 |
Return
| Return on Equity | -56.70% |
|---|---|
| Return on Assets | -45.70% |
| Return on Invested Capital | -50.23% |
Valuation & Multiples
| P/E Ratio | -5.67 |
|---|---|
| PEG | -27.41 |
| Price to Sales | - |
| Price to Book Ratio | 3.18 |
| Enterprise Value to Revenue | 23.29 |
| Enterprise Value to EBIT | -4.46 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
$21,182
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$28,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 146.19% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.29%▼ 132.23% |
|---|---|
| Total Invested | $5.38M▼ 99.76% |
| Investors Holding | 7▼ 223.00% |
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...